E. M. Zherebtsova

E. M. Zherebtsova

Auto-generated profile, based on publicly available information

E. M. Zherebtsova


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2025
Verified
Journal Article
Closed access
KEKyiv Llc “Scientific And Production Company Ecopharm”
Kyiv Llc “Scientific And Production Company Ecopharm”
EZE.M. Zherebtsova
E.M. Zherebtsova
TTT. Yu. Trokhymchuk
T. Yu. Trokhymchuk
MAM.A. Arkhipova
M.A. Arkhipova
ODO. M. Deriabin
O. M. Deriabin
SRS. L. Rybalko
S. L. Rybalko
Summary. Epidermal growth factor (EGF) and its receptors (HER/ErbB family) are essential regulators of cellular proliferation, survival, angiogenesis, and differentiation. Their dysregulation is central to the pathogenesis of various cancers and viral infections. This review analyzes the structure, ligand-binding, and dimerization of HER-1, HER-2, HER-3, and HER-4, and their downstream signaling pathways such as MAPK, PI3K, and PKC. HER-2 is emphasized as a pivotal oncogenic driver in breast, ovarian, gastric, and bladder carcinomas, where targeted therapeutics including trastuzumab, lapatinib, neratinib, and afatinib are clinically used. Resistance mechanisms and the role of heat shock protein inhibitors (e.g., ganetespib) in enhancing therapy are discussed. Additionally, EGFR-mediated pathways are shown to facilitate entry of viruses like hepatitis C and B, by exploiting host receptor complexes involving CD81 and claudin-1. The review further explores natural polyphenols (delphinidin, quercetin, EGCG) as novel EGFR/ErbB2 tyrosine kinase inhibitors with anticancer and antiviral potential. These findings underscore the multifaceted role of the EGFR/ErbB system as a target for innovative therapeutic strategies in oncology and virology. Keywords: epidermal growth factor, HER/ErbB receptors, tyrosine kinase inhibitors, targeted therapy, breast cancer, hepatitis C virus, flavonoids, EGFR inhibitors, virus entry.

15 December 2024 in Preventive medicine. Theory and practice
Verified
Journal Article
Closed access
MAM.A. Arkhypova
M.A. Arkhypova
DSD. B. Starosyla
D. B. Starosyla
TTT. Yu. Trokhymchuk
T. Yu. Trokhymchuk
YPYu. I. Porva
Yu. I. Porva
LCLlc Ukrainian Medical And Diagnostic Center
Llc Ukrainian Medical And Diagnostic Center
LELlc “Nvk Ekopharm
Llc “Nvk Ekopharm
The review highlights the current state of research on enteroviruses, in particular polioviruses, ECHO viruses, Coxsackie, and enterovirus type 71, which cause a significant number of human infectious diseases. The main aspects of their replication, pathogenesis, and molecular biological properties are discussed. Particular attention is paid to the prospects for the use of flavonoids as antiviral agents. The mechanisms of their action are analyzed, including the inhibition of proteases and blocking the interaction of viral components with cellular targets. The cytotoxicity and antiviral efficacy of a number of flavonoid compounds in model systems are considered. The review emphasizes the importance of searching for new natural substances and synthetic derivatives for the development of therapeutic agents against enterovirus infections, given the limitations of existing treatment options and the peculiarities of the mutagenicity of these viruses.

1 January 2023 in Preventive medicine. Theory and practice
Verified
Journal Article
Closed access
MAM.A. Arkhypova
M.A. Arkhypova
NINational Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic Institute”
National Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic Institute”
EZE.M. Zherebtsova
E.M. Zherebtsova
VAV.P. Atamanyuk
V.P. Atamanyuk
SUSI "L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of NAMS of Ukraine”
SI "L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of NAMS of Ukraine”
K“Kyiv Llc “Rpc “Ecopharm”
Kyiv Llc “Rpc “Ecopharm”